Investor Relations

Upcoming Events

Special Meeting of the Shareholders

Mar 26, 2019 • 8:00am EST

View All Events

Latest Financial Results

Q3 2018

Quarter Ended Sep 30, 2018

Latest Annual Filing

Fiscal Year Ended Dec 31, 2017

View Filing

Stock Information

Company Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Corporate Presentation

Corporate Presentation

Download Corporate Presentation

Investor Contact Information


Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Suite 455
Rockville, MD 20850

Investor Relations

Transfer Agent

Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Parkway
Atlantic Highlands, NJ 07716
T: 732-872-2727